Clinical Trials Directory

Trials / Completed

CompletedNCT03200704

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Single Arm, Prospective, Open Label, Multicenter Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems in the Visualization of Lymphatic Vessels and Lymph Nodes During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
152 (actual)
Sponsor
Novadaq Technologies ULC, now a part of Stryker · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures as confirmed by Technitium99m (Tc99m) and Gamma Probe.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTIC2000 and SPY-PHIInvestigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
COMBINATION_PRODUCTTc-99m radioactive colloid and Gamma ProbeComparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer

Timeline

Start date
2019-01-04
Primary completion
2020-08-27
Completion
2020-09-28
First posted
2017-06-27
Last updated
2023-09-21
Results posted
2023-09-21

Locations

7 sites across 2 countries: United States, Canada

Regulatory

Source: ClinicalTrials.gov record NCT03200704. Inclusion in this directory is not an endorsement.